CAR T-Cell Therapy During the COVID-19 Pandemic

Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL

Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL

Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase

ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia